| Stage |
Phase |
Principal Investigator |
Study prefix |
Study number |
Title
(click hyperlink for more information) |
| I | Adekunle Odunsi, MD PhD | I | 125207 | Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (vCP2292) in Patients with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen |
| III | Shashikant Lele, MD | PH | 104007 | (AVF4095g) A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma |
| I | Adekunle Odunsi, MD PhD | I | 127008 | A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination with 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
Print This Page
